|
Report No. : |
344202 |
|
Report Date : |
14.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
SUAN HONG TRADING COMPANY LTD. |
|
|
|
|
Registered Office : |
8F., No.41, Qiao'an St., Zhonghe Dist., New Taipei City 23557 |
|
|
|
|
Country : |
Taiwan |
|
|
|
|
Date of Incorporation : |
28.12.1993 |
|
|
|
|
Com. Reg. No.: |
84500155 |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business : |
Subject is engaged in trading of pharmaceutical raw materials |
|
|
|
|
No. of Employee : |
10 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Taiwan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
8F., No.41, Qiao'an St., Zhonghe Dist., New Taipei City 23557, Taiwan |
|
Supplied
Address: |
1FL 131 HUAN HO SOUTH RD SECTION 2WANHUA DIST TAIPEI CITY 108XXX
Taiwan0 |
|
Telephone
Number: |
|
|
Fax Number: |
|
|
Email: |
Notes: The exact name and address are as above. It is
introduced that supplied telephone number +886-2-2336-5826 is subject’s former
number, but they did not explain the supplied address.
|
Registered Name: |
SUAN HONG
TRADING COMPANY LTD. |
|
Registered
Address: |
8F., No.41,
Qiao'an St., Zhonghe Dist., New Taipei City 23557, Taiwan |
|
Date of
Foundation: |
1993-12-28 |
|
Registration
Number: |
84500155 |
|
Registry: |
New Taipei City
Government |
|
Registered
Capital: |
(As of 2015.10, 1
NTD = 0.0310 USD) |
|
Legal
Representatives: |
Desheng Zhan |
|
Legal Form: |
|
|
Principal
Activities: |
|
|
Staff: |
|
|
Listed at Stock
Exchange: |
|
|
Date of Last
Annual Return: |
Subject was incorporated on 1993-12-28 with registered number 84500155 as
Private Limited Liability Company in Taiwan.
Subject did not register any subsidiaries
or branches; from other source we could not obtain the relevant information,
either.
Major Shareholders
|
Name |
Subscription Amount |
|
Desheng Zhan |
|
|
6,500,000 |
Core Management
Directors
|
Name |
Desheng Zhan |
|
Position |
Director |
Personnel Structure
|
Total
Employees |
About 10 Employees |
Offices & Factories
|
|
Headquarters |
|
Add |
8F., No.41, Qiao'an
St., Zhonghe Dist., New Taipei City 23557,Taiwan |
Production Information
l Subject is a trader of pharmaceutical raw materials without
any production activities.
Purchase Information
l The registered activities of subject:
|
Business Code |
Details |
|
F108021 |
Western medicine wholesale |
|
F107070 |
Veterinary drug wholesaling |
|
F107200 |
Chemical raw materials wholesale |
|
F102170 |
Food wholesale goods |
|
F108031 |
Medical equipment wholesale |
|
F208021 |
Western medicine retail |
|
F207070 |
Animal drug retailing |
|
F207200 |
Chemical raw materials retail |
|
F203010 |
Food beverage retail goods |
|
F208031 |
Medical equipment retail |
|
F401010 |
The international trading business |
|
ZZ99999 |
Besides licensed business, all other business
items those are not banned or restricted. |
l The products sold by the subject are
purchased from the Mainland of China, India, Italy, Germany, France, USA,
l
Subject
is engaged in sale of pharmaceutical
raw materials and food additives
l The major products of the subject are
acarbose, acetaminophen (paracetamol), acetazolamide, acyclovir,
chlorpheniramine maleate, cyanocobalamine, ascorbic acid, folic acid, thiamine
hydrochloride (vitamin b1), and vitamin D3 microcapsule and so on.
l It is introduced that subject mainly sells
its products in Taiwan.
l Subject’s major customers are manufacturers
of pharmaceutical products,
Import and export
right:
|
Import right |
Yes |
|
Export right |
Yes |
Purchase
1. Domestic Purchase
|
Products |
Pharmaceutical
raw materials |
|
Payment Terms |
T/T, Cash |
2. Import
|
Products |
Pharmaceutical
raw materials |
|
Payment Terms |
L/C, T/T |
1. Domestic Markets
|
Product |
Pharmaceutical raw
materials |
|
Selling Terms |
T/T, Cash |
2. Export
Subject has little export.
Subject has no
obligations to disclose its financial statements to the third party according to
the relevant policy in Taiwan and the only source from which we can obtain the
information is the subject itself.
Subject’s relevant
staff declined to disclose its financials citing the grounds of company’s
confidentiality; from other sources we could not obtain such information,
either.
Subject declined to disclose its bank
details; from other source we could not obtain the relevant information,
either.
Mortgage
No chattel mortgage record of subject has
been found within the recent 3 months.
Lawsuit
Up to date of reporting, no existing or
latent litigation of the subject has been found.
Interview Details
|
Department |
Sales Department
|
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.02 |
|
|
1 |
Rs.99.89 |
|
Euro |
1 |
Rs.73.92 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.